Sign up to our newsletter Subscribe
Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence

Comment, press releases and other news from OHE.
Our monthly Bulletin highlights our work alongside the latest from across health economics and health care.